Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial

PURPOSE: The proPSMA trial at ten Australian centers demonstrated increased sensitivity and specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status in primary high-risk prostate cancer patients. A cost-effectiveness analysis showed benefits of PSMA PET/CT over conven...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzgreve, Adrien, Unterrainer, Marcus, Calais, Jérémie, Adams, Thaiza, Oprea-Lager, Daniela E., Goffin, Karolien, Lopci, Egesta, Unterrainer, Lena M., Kramer, Kristina K. M., Schmidt-Hegemann, Nina-Sophie, Casuscelli, Jozefina, Stief, Christian G., Ricke, Jens, Bartenstein, Peter, Kunz, Wolfgang G., Mehrens, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547650/
https://www.ncbi.nlm.nih.gov/pubmed/37428216
http://dx.doi.org/10.1007/s00259-023-06332-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547650/
https://www.ncbi.nlm.nih.gov/pubmed/37428216
http://dx.doi.org/10.1007/s00259-023-06332-y

Ejemplares similares